PT  - JOURNAL ARTICLE
AU  - Morrison, Amy E
AU  - Farnsworth, Kate
AU  - Witteman, Holly O
AU  - Lam, Anna
AU  - Senior, Peter A
TI  - Canadian Healthcare Providers’ Attitudes Towards Automated Insulin Delivery Systems
AID  - 10.1101/2022.06.02.22275169
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.02.22275169
4099  - http://medrxiv.org/content/early/2022/06/03/2022.06.02.22275169.short
4100  - http://medrxiv.org/content/early/2022/06/03/2022.06.02.22275169.full
AB  - Introduction We aimed to assess the current experience and attitudes towards Commercial and Do-it-yourself (DIY) automated insulin delivery (AID) systems among healthcare providers (HCP) across Canada.Methods A cross-sectional study was performed through electronic distribution of an anonymous survey to HCP licensed to practice in Canada looking after people with type 1 diabetes (T1D).Results Responses included 204 HCP across the multi-disciplinary team; dieticians (32.8%), nurses (31.9%), and endocrinologists (28.4%), looking after adults (51%) and children (23%) mainly in urban areas (85.7%). Respondents reported a median 100-500 patients with T1D per practice, with a median 6-24 current users/practice of Commercial compared to a median 1-5 current users/practice of DIY AID. The majority of HCP (72.7%) were comfortable supporting Commercial AID, whereas only 21.6% reported comfort supporting DIY AID use. A significant, although moderate correlation between HCP experience and comfort was seen; Commercial r=0.57(p<0.0001) and DIY r=0.45(p<0.0001). Respondents reported more barriers to DIY, relative to Commercial AID(p=0.001); unfamiliarity/lack of exposure and medico-legal risks were highlighted with DIY systems. Respondents suggested AID system education (both Commercial and DIY), for HCP and users, to improve HCP confidence.Conclusions Despite documented beneficial outcomes, AID systems are not widely used in the management of T1D in Canada. The need for both user and HCP education to improve familiarity with the systems, in addition to clarity in medico-legal guidance, have been identified as gaps, which if addressed, might enable the benefits of AID to be more widely available to people with T1D in Canada.Competing Interest StatementKF is a full-time employee of Beta Bionics and all the research associated with CANADIAN HEALTHCARE PROVIDERS' ATTITUDES TOWARDS AUTOMATED INSULIN DELIVERY SYSTEMS was completed in her capacity prior to her employment with Beta Bionics and as an independent consultant. The opinions/views expressed in this presentation/publication are her own. They do not purport to reflect the opinions or views of the Beta Bionics, its employees, agents, investors and/or board members or its members. HOW has received grants from Canadian Institutes of Health Research, Diabetes Action Canada, Canada Foundation for Innovation and Fonds de recherche du Quebec-Sante. HOW personally uses a Do-It-Yourself system. AL has received grants from Juvenile Diabetes Research Foundation and Diabetes UK. PAS has received grants from Novo Nordisk and is a Board chair for Diabetes Canada and Co-Investigator Diabetes Action Canada. Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Board of University of Alberta gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript